Skip to main content

Table 1 Clinical features of patients and response to tocilizumab

From: Mitochondrial and oxidative stress genes are differentially expressed in neutrophils of sJIA patients treated with tocilizumab: a pilot microarray study

Sample code 37-5 37-7 50-2 50-4 51-1 51-3 53-2 53-4
Sample type N N P, N P, N P, N P, N P, N P, N
Conditions Pre-TOC 12 weeks TOC Pre-TOC 12 weeks TOC Pre-TOC 12 weeks TOC Pre-TOC 12 weeks TOC
Ethnicity Caucasian Caucasian Asian Caucasian
Gender Male Female Male Female
Age at onset (AAO) 7 years 9 years 14 years 4 years
Disease duration 3.4 years 7 years 10 months 9 months
Fever Yes No No No No No Yes No
Rash Yes No No No No No No No
Total WCC (lymphocytes) x 109/L 22.22 (1.36) 10.76 (4.99) 10.51 (1.28) 5.58 (2.67) N/D 5.84 (2.52) 13.98 (4.80) 8.09 (4.03)
CRP (mg/l), 0-20 normal range 84 <5 24 <5 13.6 <3 56 <5
ESR (mm/h), 0–10 normal range 65 <1 29 3 N/D 1 35 <1
Joint active 6 0 22 10 6 0 51 0
Joint limited motion 6 0 30 12 7 0 49 3
Parental VAS N/D 0 6.8 1 2.8 0.4 5 2.2
Physician VAS 5 0 8 4 3 1 8 0.4
CHAQ 1.75 0 1.5 0.38 0 0 1.13 0.5
ACR - 90 - 90 - 90 - 90
  1. The demographics, clinical and laboratory parameters of the patients whose peripheral blood was used in this study are shown. For each patient, baseline measurements were taken before starting tocilizumab (TOC) treatment, and 12 weeks later. Normal range for total white cell count (WCC) is 4.5–13.5 × 109/L and for lymphocytes 1.5–7 × 109/L. The different types of samples taken/analysed were: PBMC = P; and Neutrophils = N. There are 3 paired samples for PBMC (P) and 4 for neutrophils (N). Response to treatment was determined by ACR90 response definition of improvement in juvenile arthritis [47], plus normalisation of the erythrocyte sedimentation rate (ESR) and C reactive protein (CRP). N/D not determined, VAS visual analogue score, CHAQ child health assessment questionnaire, ACR American College of Rheumatology